Exact Mass: 443.0951

Exact Mass Matches: 443.0951

Found 13 metabolites which its exact mass value is equals to given mass value 443.0951, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

LY2874455

1H-Pyrazole-1-ethanol, 4-((1E)-2-(5-((1R)-1-(3,5-dichloro-4-pyridinyl)ethoxy)-1H-indazol-3-yl)ethenyl)-

C21H19Cl2N5O2 (443.0916)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor

N-debutylhalofantrine

3-(butylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol

C22H22Cl2F3NO (443.103)

N-debutylhalofantrine is a metabolite of halofantrine. Halofantrine is a drug used to treat malaria. Halofantrines structure contains a substituted phenanthrene, and is related to the antimalarial drugs quinine and lumefantrine. Marketed as Halfan, halofantrine is never used to prevent malaria and its mode of action is unknown. A crystallographic study have shown that halofantrine binds to hematin in vitro, suggesting a possible mechanism of action. (Wikipedia) D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents

Selinexor

3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N-(1,2-dihydropyrazin-2-ylidene)prop-2-enehydrazonate

C17H11F6N7O (443.0929)

Desmethylhalofantrine

1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol

C22H22Cl2F3NO (443.103)

(S)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N-METHYLETHANAMINE 4-METHYLBENZENESULFONATE

C18H19F6NO3S (443.099)

CGP 54626 hydrochloride

C18H29Cl3NO3P (443.0951)

Selinexor

C17H11F6N7O (443.0929)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

OSI-930

C22H16F3N3O2S (443.0915)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

(E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide

C17H11F6N7O (443.0929)

(2E)-N-Allyl-4-{[3-(4-bromophenyl)-5-fluoro-1-methyl-1H-indazol-6-YL]oxy}-N-methyl-2-buten-1-amine

C22H23BrFN3O (443.1008)

(E)-phenyl-[(1S,3S,6R,8R,9S)-1,3,8,10-tetrahydroxy-9-(4-methoxy-6-oxopyran-2-yl)-4-oxo-5-oxatricyclo[4.3.1.03,8]decan-2-ylidene]methanolate

C22H19O10- (443.0978)

N-(5-chloro-2,4-dimethoxyphenyl)-1-methyl-4-(4-morpholinylsulfonyl)-2-pyrrolecarboxamide

C18H22ClN3O6S (443.0918)

N-[5-(1-azepanylsulfonyl)-2-chlorophenyl]-2-[(4-methyl-1,2,4-triazol-3-yl)thio]acetamide

C17H22ClN5O3S2 (443.0853)